Blood Levels of Apelin-12 in Patients with Essential Hypertension and Type 2 Diabetes and Without It Before and After Combined Therapy

K.O. Yushko

Abstract


The study included 40 patients with essential hypertension, of whom 19 patients had concomitant type 2 diabetes, before and after 12 weeks of treatment with olmesartan and lercanidipine on the background of atorvastatin therapy. Patients with type 2 diabetes were treated with metformin additionally. The control group consisted of 10 apparently healthy people. The examination included: physical methods, determination of blood lipid levels, fasting glucose, insulin with insulin resistance index calculation, studying structural and functional cardiac parameters. Apelin-12 levels were tested using enzyme immunoassay. We found that in hypertensive patients with type 2 diabetes blood levels of apelin-12 are lower than those in the group of apparently healthy individuals. Among hypertensive patients without type 2 diabetes blood levels of apelin-12 depend on diastolic blood pressure, lipid metabolism parameters, left atrium size, aortic diameter. In patients with type 2 diabetes, blood level of apelin-12 correlates with diastolic blood pressure, duration of hypertension, atherogenic factor and left atrium size. In patients with concomitant type 2 diabetes there were significantly higher levels of apelin-12 after therapy compared with its basal levels. These data confirm the participation of endogenous peptide apelin-12 in blood pressure regulation processes, atherogenesis and pathological cardiac remodeling in hypertensive patients both with type 2 diabetes, and without it.


Keywords


apelin; essential hypertension; type 2 diabetes

References


Japp A.G., Cruden N.L., Barnes G. et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure // Circulation. — 2010. — Vol. 121(16). — P. 1818-1827.

Koguchi W., Kobayashi N., Takeshima H. et al. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure // Circ. J. — 2012. — Vol. 76(1). — P. 137-144.

Papadopoulos D.P., Mourouzis I., Faselis C. et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels // J. Clin. Hypertens. (Greenwich). — 2013. — Vol. 15(5). — P. 333-336.

Tycinska A.M., Lisowska A., Musial W.J. et al. Apelin in acute myocardial infarction and heart failure induced by ischemia // Clin. Chim. Acta. — 2012. — Vol. 413(3–4). — P. 406-410.

Писаренко О.П., Серебрякова Л.И., Пелогейкина Ю.А. и соавт. Участие NO-зависимых механизмов действия апелина в защите миокарда от ишемического и реперфузионного повреждения // Кардиология. — 2012. — № 2. — С. 52-58.

Dray C., Knauf C., Daviaud D. et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice // Cell. Metab. — 2008. — Vol. 8. — P. 437-445.

Shiming Xu, Philip S. Tsao, Patrick Yue. Apelin and insulin resistance: another arrow for the quiver? // J. Diabetes. — 2011. — Vol. 3(3). — P. 225-231.

Zheng Tian-Peng, Guo Chang-Hui, Zhou Ting-Ting et al. The relationship between plasma apelin-12 level and hypertension, insulin resistance of type 2 diabetes mellitus patients // Chinese Journal of Gerontology. — 2010. — Issue 4. — P. 435-437.

Barnes G., Japp A.G., Newby D.E. Translational promise of the apelin-APJ system // Heart. — 2010. — Vol. 96(13). — P. 1011-1016.

Lv D., Li H., Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis // Acta Biochim. Biophys. Sin. (Shanghai). — 2013. — Vol. 45(7). — P. 527-533.

Seyyed M.R. Kazemi-Bajestani, Vaibhav B. Patel, Wang Wang et al. Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges // Cardiology Research and Practice. — 2012. — Vol. 2012. — Article ID 823193, 11 pages.

Isabelle Castan-laurell, Cédric Dray, Claude Knauf. Apelin, a promising target for type 2 diabetes treatment? // Trends in Endocrinology & Metabolism. — 2012. — Vol. 23(5). — P. 234-241.

Erdem G., Dogru T., Tasci I. et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus // Exp. Clin. Endocrinol. Diabetes. — 2008. — Vol. 116(5). — P. 289-92.

Cavallo M.G., Sentinelli F., Barchetta I. et al. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus // PLoS One. — 2012. — Vol. 7(12). — e51236.

Soriguer F., Garrido-Sanchez L., Garcia-Serrano S. et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus // Obes. Surg. — 2009. — Vol. 19(11). — P. 1574-1580.

Pitkin S.L., Maguire J.J., Bonner T.I. et al. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function // Pharmacol. Rev. — 2010. — Vol. 62(3). — P. 331-342.

Tasci I., Dogru T., Nacharci I. et al. Plasma apelin is lower in patients with elevated LDL-cholesterol // Exp. Clin. Endocrinol. Diabetes. — 2007. — Vol. 115 (7). — P. 428-432.

Falcone C., Buzzi M.P., Dangelo A. et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation // Int. J. Immunopathol. Pharmacol. — 2010. — Vol. 23. — P. 917-925.

Kallergis E.M., Manios E.G., Kanoupakis E.M. et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation // Am. J. Cardiol. — 2010. — Vol. 105(1). — P. 90-94.

Baysal S.S. et al. Сhange in apelin level in response to treatment and relation with diastolic function in patients with newly diagnosed hypertension // Int. J. of Card. — 2013. — 163S1. – S15-15.




DOI: https://doi.org/10.22141/2224-1485.3.35.2014.82725

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru